Publications by authors named "O Bylicki"

Claim this Profile
R
Rebiopsy Feasibility and Clinical Impact on Metastatic Non-Small-Cell Lung Cancer With EGFR/ALK/ROS Oncogenic Driver Progression After Optimal Targeted Therapy: A Multicenter Real-World Analysis.
Antoine Bronstein, Hubert Curcio, Isabelle Monnet, Charles Ricordel, Laurence Bigay-Game, Olivier Bylicki

Clin Lung Cancer· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant chemotherapy for stage IA-IIA non-squamous, non-small-cell lung cancer identified as molecular high-risk by a 14-gene expression profile (AIM-HIGH): an international, randomised, phase 3 trial.
David R Spigel, Virginie Westeel, Ian C Anderson, Laurent Greillier, Florian Guisier, Olivier Bylicki

Lancet Respir Med· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to the Letter of Mehmet Mutlu Çatlı, Arif Hakan Önder.
Antoine Bronstein, Olivier Bylicki, Christos Chouaid

Clin Lung Cancer· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alectinib Efficacy Post-Brigatinib Against Advanced + Non-Small Cell Lung Cancer (BrigALK2-GFPC 02-2019 Study).
Renaud Descourt, Florian Guisier, Maurice Pérol, Jacques Cadranel, Helene Doubre, Olivier Bylicki

Lung Cancer (Auckl)· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Osimertinib - maintenance therapy after radiochemotherapy for locally advanced non-small cell lung cancer with EGFR exon 19 deletion or exon 21 L858R mutation].
Lisa Bosquain, Olivier Bylicki

Bull Cancer· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis